// App-Quantinova.ai

7538 : Feasibility of real-time cell-of-origin subtype identification by gene expression profile in the phase 3 trial of lenalidomide plus R-CHOP vs placebo plus R-CHOP in patients with untreated ABC-type diffuse large B-cell lymphoma (ROBUST).

Researchers

Presenter

  • Grzegorz S. Nowakowski

Principal Investigators

  • Annalisa Chiappella

  • Thomas E. Witzig

  • Michele Spina

  • Randy D. Gascoyne

  • Lei Zhang

  • Jocelyne Flament

  • Jacqueline Repici

  • Erin Conlin

  • Krista Delissio

  • Umberto Vitolo

Medical Centers

  • Mayo Clinic, Rochester, MN

  • Division of Hematology, Citta della Salute e della Scienza Hospital and University, Torino, Italy

  • National Cancer Institute, Aviano, Italy

  • British Columbia Cancer Agency, Vancouver, BC, Canada

  • Celgene Corporation, Summit, NJ

Locations

  • United States

  • Canada

  • Italy

Companies

  • Celgene Corporation

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Diffuse large B-cell lymphoma

Biomarkers

  • B-lymphocyte antigen CD20

  • Granulin precursor

Drug/Treatment

  • Lenalidomide

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • III

Study Id's

  • NCT02285062

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved